

# Olga Kondrashova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7191887/publications.pdf>

Version: 2024-02-01

20  
papers

1,125  
citations

759233

12  
h-index

839539

18  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1517  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. <i>Genome Medicine</i> , 2022, 14, 3.	8.2	16
2	CRISPR/Cas9-mediated genome editing of <i>Schistosoma mansoni</i> acetylcholinesterase. <i>FASEB Journal</i> , 2021, 35, e21205.	0.5	21
3	Histone Modifying Enzymes in Gynaecological Cancers. <i>Cancers</i> , 2021, 13, 816.	3.7	10
4	Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. <i>Cancers</i> , 2021, 13, 1762.	3.7	5
5	Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	3.1	20
6	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.9	42
7	Deep learning in cancer diagnosis, prognosis and treatment selection. <i>Genome Medicine</i> , 2021, 13, 152.	8.2	274
8	Verifying explainability of a deep learning tissue classifier trained on RNA-seq data. <i>Scientific Reports</i> , 2021, 11, 2641.	3.3	32
9	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2020, 11, 2641.	12.8	90
10	NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 103-103.	1.6	3
11	Diverse mechanisms of PARP inhibitor resistance in ovarian cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 188307.	7.4	14
12	Clarifying the role of EMSY in DNA repair in ovarian cancer. <i>Cancer</i> , 2019, 125, 2720-2724.	4.1	6
13	Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	3.0	0
14	Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018, 244, 586-597.	4.5	41
15	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. <i>Human Mutation</i> , 2018, 39, 394-405.	2.5	24
16	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	12.8	192
17	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	9.4	310
18	Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5583-5583.	1.6	0

#	ARTICLE	IF	CITATIONS
19	High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq. PLoS ONE, 2015, 10, e0143006.	2.5	11
20	AmpliVar: Mutation Detection in High-Throughput Sequence from Amplicon-Based Libraries. Human Mutation, 2015, 36, 411-418.	2.5	7